Format

Send to

Choose Destination
Rheumatol Int. 2019 Oct;39(10):1697-1702. doi: 10.1007/s00296-019-04433-2. Epub 2019 Aug 30.

Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina.

Author information

1
Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Peron 4190, Ciudad Autonoma de Buenos Aires, 1199, Buenos Aires, Argentina. martin.brom@hospitalitaliano.org.ar.
2
University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. martin.brom@hospitalitaliano.org.ar.
3
Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Peron 4190, Ciudad Autonoma de Buenos Aires, 1199, Buenos Aires, Argentina.
4
University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Abstract

Primary Sjögren syndrome (pSS) is usually a mild disease, but serious complications such as non-Hodgkin lymphoma-and hypothetically other malignancies-may develop. The aim of this study was to evaluate both overall and specific incidence of cancer in a cohort of patients with pSS compared to the expected incidence in general population of Argentina. Retrospective analytic study of pSS patients fulfilling American-European Consensus Group (AECG) criteria, followed from the time of their diagnosis until the end of the study, death, loss of follow- up, or being given a diagnosis of cancer. Cancer incidence for the general population was obtained from GLOBOCAN 2018, and demographic information was obtained from the national institute for statistics and census. Age- and sex-specific Standardized Incidence Ratio (SIR) were then calculated. One hundred fifty-seven patients, with a mean age of 57.8 years (SD 18.3), were included. Mean patient follow-up duration was 7.37 years (SD 4.2), contributing to a total of 1158 patient/years. Fifteen patients developed a malignancy during follow-up. Cancer incidence for pSS patients was compared with the general population's incidence through SIRs. Female patient's SIRs for overall cancer was 4.17 (95% CI 2.30-6.87), non-Hodgkin lymphoma 41.40 (95% CI 10.12-102.1), multiple myeloma 41.49 (95% CI 1.14-167.28), tongue cancer 44.4 (95% CI 1.23-177.31), uterus cancer 8.39 (95% CI 0.19-40.73), lung cancer 4.51 (95% CI 0.1-22.16), and breast cancer 3.76 (95% CI 1.04-9.45). An increased overall cancer risk, and particularly for non-Hodgkin lymphoma, multiple myeloma, breast cancer and tongue cancer was observed in female pSS patients compared to control group.

KEYWORDS:

Hematologic neoplasms [D019337]; Lymphoma; Neoplasms [D009369]; Non-Hodgkin [D008228]; Sjogren’s syndrome [D012859]

PMID:
31471716
DOI:
10.1007/s00296-019-04433-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center